Vimarsana
Biggest News Aggregation in the World

Page 12 - Improving Safety News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Improving Safety. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Improving Safety Today - Breaking & Trending Today

Rental's Top 10 Stories from 2020 | For Construction Pros - Vimarsana News

Rental's Top 10 Stories from 2020 | For Construction Pros

This was my first piece for  Rental back in May 2020, an introduction letter to give readers more insight about who I am and my background. Looking back at that nervous new editor from seven months ago, I can’t help but smile. This change has been such a highlight of my year, and as I wrote in the piece,  “If this quarantine period has taught us anything, it’s that change can be a good thing in one way or another. I’m here to prove that to you.”   Ditch Witch shares with us a few different reasons how and why vacuum excavators are becoming more popular throughout the ...

U.S. FDA Approves Supplemental New Drug Application for Takeda's ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML - Vimarsana News

U.S. FDA Approves Supplemental New Drug Application for Takeda's ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML

Takeda Pharmaceutical Company Limited U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML Saturday, December 19, 2020 2:19PM IST (8:49AM GMT)    – Updated ICLUSIG Label will Prove Practice-Changing, Expanding Indication to CP-CML Patients with Resistance or Intolerance to At Least Two Prior Tyrosine Kinase Inhibitors (TKIs) – ­– Approval Based on Data from the Phase 2 OPTIC Trial, Which Evaluated Response-Based ICLUSIG Dosing Regimens in CP-CML – – New Dosing Regimen in CP-CM...